Telik: FDA removes partial hold on lung cancer drug candidate

Oct 15 (Reuters) - Telik Inc (TELK.O) said the U.S. Food and Drug Administration removed the partial hold on clinical trials of its lung cancer drug candidate Telcyta, after a complete review of the data by the agency.

The regulators permitted the resumption of the drug's clinical development, the biotechnology company said in a statement. (Reporting by Ramya Dilip in Bangalore)